Evaluation of Novel Therapeutic Agents Against Breast Cancer: An Innovative Randomized Phase II Trial Design.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Interleukin-12 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 15 Jul 2016 Status changed from discontinued to completed.
- 16 Oct 2013 Lead trial centre amended as reported by ClinicalTrials.gov.
- 02 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.